DE3486053D1 - Regulierung von gen-expression durch translationshemmung unter verwendung von m-rns hinderndem komplementaer-rns. - Google Patents

Regulierung von gen-expression durch translationshemmung unter verwendung von m-rns hinderndem komplementaer-rns.

Info

Publication number
DE3486053D1
DE3486053D1 DE8484112647T DE3486053T DE3486053D1 DE 3486053 D1 DE3486053 D1 DE 3486053D1 DE 8484112647 T DE8484112647 T DE 8484112647T DE 3486053 T DE3486053 T DE 3486053T DE 3486053 D1 DE3486053 D1 DE 3486053D1
Authority
DE
Germany
Prior art keywords
rns
gene
complementary
regulation
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8484112647T
Other languages
English (en)
Other versions
DE3486053T2 (de
DE3486053T3 (de
Inventor
Masayori Inouye
Takeshi Mizuno
Mei-Yin Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27067361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3486053(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Application granted granted Critical
Publication of DE3486053D1 publication Critical patent/DE3486053D1/de
Publication of DE3486053T2 publication Critical patent/DE3486053T2/de
Publication of DE3486053T3 publication Critical patent/DE3486053T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DE3486053T 1983-10-20 1984-10-19 Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS. Expired - Lifetime DE3486053T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54352883A 1983-10-20 1983-10-20
US58528284A 1984-03-01 1984-03-01
US585282 1984-03-01
US543528 1984-03-01

Publications (3)

Publication Number Publication Date
DE3486053D1 true DE3486053D1 (de) 1993-03-11
DE3486053T2 DE3486053T2 (de) 1993-05-19
DE3486053T3 DE3486053T3 (de) 2004-01-08

Family

ID=27067361

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3486053T Expired - Lifetime DE3486053T3 (de) 1983-10-20 1984-10-19 Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
DE3486479T Expired - Lifetime DE3486479T2 (de) 1983-10-20 1984-10-19 Regulierung der Genexpression durch Translationshemmung unter Verwendung von mRNA hindernder Komplementär-RNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3486479T Expired - Lifetime DE3486479T2 (de) 1983-10-20 1984-10-19 Regulierung der Genexpression durch Translationshemmung unter Verwendung von mRNA hindernder Komplementär-RNA

Country Status (5)

Country Link
EP (2) EP0140308B2 (de)
JP (2) JP2651442B2 (de)
AT (1) ATE198350T1 (de)
CA (1) CA1341091C (de)
DE (2) DE3486053T3 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
ATE202139T1 (de) * 1985-03-21 2001-06-15 Johnston Stephen Ph D Von parasit gewonnener widerstand
US6617496B1 (en) 1985-10-16 2003-09-09 Monsanto Company Effecting virus resistance in plants through the use of negative strand RNAs
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO1998014567A2 (en) * 1996-10-01 1998-04-09 Advanced Research & Technology Institute Methods and compositions for inhibiting bacterial growth
EP0837142A1 (de) * 1996-10-15 1998-04-22 Smithkline Beecham Corporation Verfahren zum Nachweis essentieller Gene eines Erregers
US6139817A (en) * 1996-10-15 2000-10-31 Smithkline Beecham Corporation Method for determining gene essentiality in a pathogen
CA2270153A1 (en) * 1996-11-06 1998-05-14 Smithkline Beecham Corporation Methods for identifying genes essential to the growth of an organism
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US6483009B1 (en) 1997-02-21 2002-11-19 Danisco A/S Antisense intron inhibition of starch branching enzyme expression
CA2254785A1 (en) * 1997-03-10 1998-09-17 Japan Tobacco Inc. Antisense base sequences
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
WO1999035241A1 (en) 1998-01-08 1999-07-15 Aventis Pharmaceuticals Products Inc. Transgenic rabbit that expresses a functional human lipoprotein (a)
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
ATE507299T1 (de) 1998-04-08 2011-05-15 Commw Scient Ind Res Org Verfahren und mittel zum erhalt von veränderten phänotypen
US7148400B1 (en) 1999-04-20 2006-12-12 Bayer Bioscience N.V. Methods and means for delivering inhibitory RNA to plants and applications thereof
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
KR100811571B1 (ko) 2000-03-31 2008-03-10 아벤티스 파마슈티칼스 인크. 핵 인자 κＢ 유도 인자
CA2416289C (en) 2000-07-21 2012-12-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7192771B2 (en) 2000-08-30 2007-03-20 North Carolina State University Plant promoter sequence
AU1480402A (en) 2000-11-09 2002-05-21 Commw Scient Ind Res Org Barley with reduced SSII activity and starch containing products with a reduced amylopectin content
IL159213A0 (en) 2001-06-08 2004-06-01 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
US7491506B2 (en) 2001-06-21 2009-02-17 The Regents Of The University Of California Inhibition of B-cell maturation and antibody production
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
EP1479985B1 (de) 2002-01-17 2017-06-14 Alfa Laval Corporate AB Getauchter Verdampfer umfassend einen Plattenwärmetauscher und ein zylindrisches Gehäuse in dem der Plattenwärmetauscher angeordnet ist
AU2003209814B2 (en) 2002-03-14 2008-12-04 Commonwealth Scientific & Industrial Research Organisation Modified gene-silencing RNA and uses thereof
DE10212892A1 (de) 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
US7812221B2 (en) 2003-06-30 2010-10-12 Commonwealth Scientific And Industrial Research Organization Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom
WO2005033275A2 (en) 2003-09-29 2005-04-14 The Regents Of The University Of California Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
US7129042B2 (en) 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
JP5638736B2 (ja) 2004-12-30 2014-12-10 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 腸の健康を改善する方法および手段
FR2881143B1 (fr) 2005-01-27 2010-12-17 Librophyt Systeme de production de terpenoides dans les plantes
WO2007092471A2 (en) 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP2436769B1 (de) 2006-06-07 2015-04-01 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pflanzenexpressionskonstrukte und Verfahren zu deren Verwendung
MY151438A (en) 2006-07-28 2014-05-30 Sanofi Aventis Compositions and method for treatment of tumors
JP2011507506A (ja) 2007-12-21 2011-03-10 ケイヘーネ・エヌ・ブイ トリコーム特異的なプロモーター
EP2100962A1 (de) 2008-03-12 2009-09-16 Biogemma Pflanzen mit verbesserter Widerstandsfähigkeit gegen Pathogene
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
EP2249160A1 (de) 2009-04-27 2010-11-10 Centre National de la Recherche Scientifique VDAC3-S als ein Zellmarker
CN102459615B (zh) 2009-06-08 2017-05-03 纽海姆有限公司 耐旱植物
WO2011147968A1 (en) 2010-05-28 2011-12-01 Nunhems B.V. Plants with increased fruit size
EP2525224A1 (de) 2011-05-19 2012-11-21 Centre National de la Recherche Scientifique VDAC1-S als ein Zellmarker
FR2986803A1 (fr) 2012-02-13 2013-08-16 Apex Biosolutions Cytomegalovirus humain oncogenique
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
WO2017039452A1 (en) 2015-09-04 2017-03-09 Keygene N.V. Diplospory gene
FR3081169B1 (fr) 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS581451Y2 (ja) * 1979-11-13 1983-01-11 浜野 純一 自動充填機における袋供給送り装置

Also Published As

Publication number Publication date
DE3486053T2 (de) 1993-05-19
DE3486479D1 (de) 2001-02-01
ATE198350T1 (de) 2001-01-15
DE3486053T3 (de) 2004-01-08
EP0467349A1 (de) 1992-01-22
DE3486479T2 (de) 2001-09-20
EP0140308A2 (de) 1985-05-08
EP0140308A3 (en) 1987-05-27
EP0140308B2 (de) 2001-10-17
JP2694924B2 (ja) 1997-12-24
EP0140308B1 (de) 1993-01-27
JPS60232092A (ja) 1985-11-18
EP0467349B1 (de) 2000-12-27
JP2651442B2 (ja) 1997-09-10
CA1341091C (en) 2000-09-05
JPH09135686A (ja) 1997-05-27

Similar Documents

Publication Publication Date Title
DE3486053T2 (de) Regulierung von gen-expression durch translationshemmung unter verwendung von m-rns hinderndem komplementaer-rns.
ES2056799T3 (es) Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
ATE27000T1 (de) Expression von polypeptiden in hefen.
ES2085245T1 (es) Procedimiento para aislar acido nucleico.
AU560340B2 (en) Rennin from recombinant dna
DK97784D0 (da) Dna-segment
MX428A (es) Region regulatoria para expresion de gen heterologa en levadura.
DE3851399T2 (de) Transientes Expressionssystem zur Herstellung von rekombinantem Protein.
DE3854125T2 (de) VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.
ATE353970T1 (de) Methode zur selektion hoch-exprimierender wirtszellen
DE3688336T2 (de) Verfahren zur Herstellung von organischen Säuren unter Verwendung von Mikroorganismen.
CA2169631A1 (en) A novel homeobox factor which stimulates insulin expression in pancreatic islet cells
DE69126053T2 (de) Modifizierte Transkriptionskontrolleinheit und ihre Verwendung
ES2013353A6 (es) Metodo de adn recombonante para producir proteinas fijadoras de oxigeno, particularmente hemoglobinas.
EP0837931A4 (de) Methode zur expression in und isolation von biologisch aktiven molekülen aus urin
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
DE3682733D1 (de) Plasmidvektor und ein verfahren zur regulierung der genexpression unter verwendung dieses vektors.
DK125289A (da) Dna-struktur, omfattende en aktivator-stimuleret promotor til udtrykkelse af et oensket protein, samt fremgangsmaade til udtrykkelse af proteinet ved hjaelp af dna-strukturen
ATA282386A (de) Verfahren zur expression von genen in hefe und dna-fragmente und diese dna-fragmente enthaltende plasmide zur verwendung bei diesem verfahren
Costanzo et al. PKC-dependent phosphorylation of the p97 repressor regulates the transcription of aldolase A L-type promoter
DE59911877D1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
ATE85078T1 (de) Regulierung von gen-expression durch translationshemmung unter verwendung von m-rns hinderndem komplementaer-rns.
WO2003018803A1 (fr) Precurseurs de cellules adipeuses etablis, procede de fourniture, et procede d'utilisation
DD138784A5 (de) Verfahren zur kontinuierlichen fermentation von mikroorganismen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings